Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2017

Feb 01, 2018

SELL
$14.23 - $21.28 $1.43 Million - $2.14 Million
-100,399 Closed
0 $0
Q3 2017

Oct 23, 2017

SELL
$13.6 - $19.87 $1.66 Million - $2.42 Million
-121,942 Reduced 54.84%
100,399 $2 Million
Q2 2017

Aug 10, 2017

BUY
N/A
222,341
222,341 $3.52 Million

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $2.28B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Nationwide Fund Advisors Portfolio

Follow Nationwide Fund Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nationwide Fund Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Nationwide Fund Advisors with notifications on news.